LGND vs XNCR
LGND: Ligand Pharmaceuticals is a high-margin, asset-light biopharmaceutical firm that earns royalties and milestone payments from a diverse portfolio of licensed drug development programs and its proprietary Captisol formulation technology. XNCR: A clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines using its proprietary protein engineering platforms to treat cancer and autoimmune diseases.
Side-by-side fundamentals
| Metric | LGND | XNCR | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $280.18 | $27.80 | |
| Market cap as of 2026-08-24 | $5.6B | $2.1B | |
| P/E as of 2026-08-24 | 37.74 | n/a | |
| PEG as of 2026-08-24 | 1.80 | n/a | |
| Net margin as of 2026-08-24 | +56.0% | -155.6% | LGND higher |
| Gross margin as of 2026-08-24 | +95.3% | n/a | |
| Operating margin as of 2026-08-24 | +34.5% | -208.9% | LGND higher |
| ROE as of 2026-08-24 | +16.2% | -28.7% | LGND higher |
| ROA as of 2026-08-24 | +11.1% | -20.4% | LGND higher |
| Debt / equity as of 2026-08-24 | 0.45 | 0.21 | XNCR lower |
| Revenue growth (YoY) as of 2026-08-24 | n/a | -33.2% | |
| Revenue CAGR (3y) SEC XBRL | +11.0% | -8.6% | LGND higher |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-08-24 | 0.98 | 0.89 | |
| 1-year return as of 2026-08-24 close | +76.1% | +273.7% | XNCR higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.